After downsizing for several months, Catalyst Biosciences is getting ready to tap out. The San Francisco biotech announced Wednesday that it would be liquidating and distributing cash back to shareholders, with total proceeds expected to reach $65 million. Catalyst intends to return the money “as soon as practicable,” the company…
...